Celyad Oncology S.A.
NASDAQ: CYAD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Georges Rawadi
- Employees
- 35
- Headquarters
- Mont-Saint-Guibert, Belgium
- IPO year
- 2015
- Market cap
- $14.2M
- Website
- https://www.celyad.com
Loading CYAD…
Loading profile data…Frequently asked questions about CYAD
What does Celyad Oncology S.A. (CYAD) do?
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phas...
Where does CYAD trade?
Celyad Oncology S.A. (CYAD) trades on the NASDAQ Global Market.
What sector is CYAD in?
Celyad Oncology S.A. (CYAD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Celyad Oncology S.A.?
Georges Rawadi is the chief executive officer of Celyad Oncology S.A. (CYAD).
Where is Celyad Oncology S.A. headquartered?
Celyad Oncology S.A. is headquartered in Belgium.
Does CYAD pay a dividend?
Celyad Oncology S.A. (CYAD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYAD go public?
Celyad Oncology S.A. (CYAD) completed its initial public offering in 2015.
Is CYAD an ADR?
Yes — CYAD is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Celyad Oncology S.A. reporting and dividends follow the underlying issuer.